Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agents von Bovy, P.R., Tjoeng, F.S., Rico, J.G., Rogers, T.E., Lindmark, R.J., Zablocki, J.A., Garland, R.B., McMackins, D.E., Dayringer, H., Tóth, M.V., Zupec, M.E., Rao, S., Panzer-Knodle, S.G., Nicholson, N.S., Salyers, A., Taite, B.B., Herin, M., Miyano, M., Feigen, L.P., Adams, S.P.

Volltext

A new method for measurement of plasma concentration of orally active glycoprotein IIb/IIIa antagonists von Salyers, A.K., Szalony, J.A., Taite, B.B., Haas, N.F., Mehrotra, D.V., Feigen, L.P., Nicholson, N.S.

Volltext

In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent von Nicholson, N.S., Panzer-Knodle, S.G., Salyers, A.K., Taite, B.B., King, L.W., Miyano, M., Gorczynski, R.J., Williams, M.H., Zupec, M.E., Tjoeng, F.S., Adams, S.P., Feigen, L.P.

Volltext